レナリドミド
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, ph…
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.Blood. 2019 May 17. pii: blood-2018-10-879643. doi: 10.1182/blood-2018-10-879643.PMID: 31101627 SAKK 35/10はSwiss Group for Clinical…
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.Blood. 2017 Dec 14;130(24):2610-2618. いくつかの細胞遺伝学的異常は骨髄腫の予後に悪影響を及ぼすことが知られている。第3相試験であるTO…
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myelomaBlood 2018;131:301-310 今回のFIRST試験の最終解析では、新規に診断された多発性骨髄腫(NDMM)患者で移植の適応が無く、レナリドミドと低用量デ…
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma(Blood 2018;131:301-310) 今回のFIRST試験の最終解析では、新規に診断された多発性骨髄腫(NDMM)患者で移植の適応が無く、レナリドミドと低用量…
